ARGX 110

Drug Profile

ARGX 110

Alternative Names: Anti-CD70 SIMPLE Antibody; ARGX-110

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD70 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Haematological malignancies; Nasopharyngeal cancer; Solid tumours
  • Preclinical Autoimmune disorders; Cutaneous T cell lymphoma

Most Recent Events

  • 15 Mar 2017 argenx plans proof-of-concept phase II trial for Cutaneous T-cell lymphoma
  • 15 Dec 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy) in Switzerland (IV) (NCT03030612)
  • 06 Dec 2016 Updated efficacy and adverse events data from a phase I trial in T-cell lymphoma released by arGEN-X
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top